AGEN

5.9702.77%
SJ

Steven J. O’Day

Chief Medical Officer

Dr. Steven J. O’Day, MD, Ph.D., has been Chief Medical Officer at Agenus Inc. since January 2021. Dr. O’Day’s leadership in the immuno-oncology field spans three decades. Dr. O’Day serves as Member of Scientific Advisory Board at ImmunSYS, Inc. He was part of a small group of investigators to treat the first patients with the first checkpoint antibody, an anti-CTLA-4 molecule, ipilimumab. He presented the seminal data at the plenary session at ASCO in 2010 which demonstrated the curative potential of anti-CTLA-4 and its long and durable survival benefit in patients with metastatic melanoma. These data led to the FDA approval of ipilimumab the following year. Dr. O’Day is presenting clinical outcomes on next-generation anti-CTLA-4 molecule, AGEN1181, at SITC 2020 starting on November 11th. Dr. O’Day has been a principal investigator for more than 200 clinical trials, including international pivotal trials in which he has held leadership roles. He serves as Executive Director of the John Wayne Cancer Institute and Cancer Clinics at Providence St. John’s Health Center and Director of the Melanoma and Cutaneous Oncology Research Center. Dr. O’Day is the Director of Providence Los Angeles Regional Research, and a Professor of Medical Oncology. After receiving his BA in chemistry from Williams College in 1983, Dr. O’Day was selected as a visiting scholar in philosophy and medical ethics at Oxford University. A board-certified medical oncologist, he is recognized as one of the world’s preeminent melanoma specialists and a leader of immune-based therapies across many cancer types. Dr. O’Day has been at the forefront of new drug development and immunotherapies for cancers over the last two decades and has been a principal investigator for more than 100 clinical trials. He played a leadership role in the development of the breakthrough immune checkpoint inhibitor ipilimumab as well as the anti- PD1 antibodies pembrolizumab and nivolumab. He received his MD and completed his Internal Medicine Residency at Johns Hopkins University School of Medicine followed by a Medical Oncology and Bone Marrow Transplant Fellowship at the Dana Farber/Harvard Cancer Center. Dr. O’Day completed his medical training was at Johns Hopkins in Baltimore and the Dana Farber Cancer Institute in Boston.

Positions